Slightly Elevated High-Sensitivity C-Reactive Protein (hsCRP) Concentrations Are Associated With Carotid Atherosclerosis in Women With Varying Degrees of Glucose Tolerance

Angiology

Volumn 61, Issue 8, 2010, Pages 793-801

  Prahl, Ulrica ^a   Wikstrand, John ^a   BergstrãƒÂ¶m, GãƒÂ¶ran M L ^a,b   Behre, Carl Johan ^a   Hulthe, Johannes ^a   Fagerberg, Björn ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

atherosclerosis; C IMT; glucose tolerance; hsCRP; inflammation; ultrasound; women

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ARTICLE; BLOOD; CAROTID ARTERY; CAROTID ARTERY DISEASE; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTIMA; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUNICA MEDIA;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CAROTID ARTERIES; CAROTID ARTERY DISEASES; FEMALE; HUMANS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUNICA INTIMA; TUNICA MEDIA;

EID: 78049436951     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710370959     Document Type: Article

References (62)

1. Fagerberg B, Behre CJ, Wikstrand J, Hulten LM, Hulthe J. C-reactive protein and tumor necrosis factor-alpha in relation to insulin-mediated glucose uptake, smoking and atherosclerosis. Scand J Clin Lab Invest. 2008: 1-8; [Epub ahead of print].
2. Calabro P, Golia E, Yeh ET. CRP and the risk of atherosclerotic events. Semin Immunopathol. 2009; 31(1):79-94.
3. Yang EY, Nambi V, Tang Z, et al. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2009; 54(25):2388-2395.
4. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009; 54(23):2129-2138.
5. McNeill AM, Katz R, Girman CJ, et al. Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study. J Am Geriatr Soc. 2006; 54(9):1317-1324.
6. Hong Y, Jin X, Mo J, et al. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality-results of prospective analysis for the Atherosclerosis Risk in Communities study. J Intern Med. 2007; 262(1):113-122.
7. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999; 282(22):2131-5.
8. Lee CC, Adler AI, Sandhu MS, et al. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia. 2009; 52(6):1040-1047.
9. Hofso D, Ueland T, Hager H, et al. Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. Eur J Endocrinol. 2009; 161(3): 451-458.
10. Suurkula M, Agewall S, Fagerberg B, Wendelhag I, Widgren B, Wikstrand J. Ultrasound evaluation of atherosclerotic manifestations in the carotid artery in high-risk hypertensive patients. Risk Intervention Study (RIS) Group. Arterioscler Thromb. 1994; 14(8):1297-1304.
11. Wendelhag I, Wiklund O, Wikstrand J. Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries. Atherosclerosis 1995; 117(2):225-236.
12. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96(5):1432-1437.
13. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997;146(6): 483-494.
14. Agewall S, Wikstrand J, Fagerberg B. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men. J Hypertens. 1998;16(4):537-541.
15. Baldassarre D, De Jong A, Amato M, et al. Carotid intima-media thickness and markers of inflammation, endothelial damage and hemostasis. Ann Med. 2008;40(1):21-44.
16. Spence JD. Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease. Am J Cardiol. 2002; 89(4A):10B-15B; discussion 15B-16B.
17. Gronholdt ML, Sillesen H, Wiebe BM, Laursen H, Nordestgaard BG. Increased acute phase reactants are associated with levels of lipoproteins and increased carotid plaque volume. Eur J Vasc Endovasc Surg. 2001;21(3):227-234.
18. Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation. 2001;104(1):63-67.
19. Elias-Smale SE, Kardys I, Oudkerk M, Hofman A, Witteman JC. C-reactive protein is related to extent and progression of coronary and extra-coronary atherosclerosis; results from the Rotterdam study. Atherosclerosis. 2007;195(2):e195-e202.
20. Blackburn R, Giral P, Bruckert E, et al. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol. 2001;21(12):1962-1968.
21. Hulthe J, Wikstrand J, Fagerberg B. Relationship between C-reactive protein and intima-media thickness in the carotid and femoral arteries and to antibodies against oxidized lowdensity lipoprotein in healthy men: the Atherosclerosis and Insulin Resistance (AIR) study. Clin Sci (Lond). 2001;100(4): 371-378.
22. Chapman CM, Beilby JP, McQuillan BM, Thompson PL, Hung J. Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke. 2004;35(7):1619-1624.
23. Makita S, Nakamura M, Hiramori K. The association of C-reactive protein levels with carotid intima-media complex thickness and plaque formation in the general population. Stroke. 2005;36(10):2138-2142.
24. Rosvall M, Engstrom G, Janzon L, Berglund G, Hedblad B. The role of low grade inflammation as measured by C-reactive protein levels in the explanation of socioeconomic differences in carotid atherosclerosis. Eur J Public Health. 2007;17(4):340-347.
25. Chen K, Lindsey JB, Khera A, et al. Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study. Diab Vasc Dis Res. 2008;5(2):96-101.
26. Halvorsen S, Risoe C. Symptoms and diagnosis of coronary heart disease in women [Article in Norwegian]. Tidsskr Nor Laegeforen. 2009;129(18):1853-1857.
27. Sztajzel R. Ultrasonographic assessment of the morphological characteristics of the carotid plaque. Swiss Med Wkly. 2005; 135(43-44):635-643.
28. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1): 20-28.
29. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005;45(10): 1644-1648.
30. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol. 2003;92(4B):17K-22K.
31. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
32. Brohall G, Behre CJ, Hulthe J, Wikstrand J, Fagerberg B. Prevalence of diabetes and impaired glucose tolerance in 64-year-old Swedish women: experiences of using repeated oral glucose tolerance tests. Diabetes Care. 2006;29(2):363-367.
33. Behre CJ, Brohall G, Hulthe J, Fagerberg B. Serum adiponectin in a population sample of 64-year-old women in relation to glucose tolerance, family history of diabetes, autoimmunity, insulin sensitivity, C-peptide, and inflammation. Metabolism. 2006; 55(2):188-194.
34. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6): 499-502.
35. Wendelhag I, Gustavsson T, Suurkula M, Berglund G, Wikstrand J. Ultrasound measurement of wall thickness in the carotid artery: fundamental principles and description of a computerized analysing system. Clin Physiol. 1991;11(6):565-577.
36. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21(2):93-111; quiz 189-190.
37. Schmidt C, Wendelhag I. How can the variability in ultrasound measurement of intima-media thickness be reduced? Studies of interobserver variability in carotid and femoral arteries. Clin Physiol. 1999;19(1):45-55.
38. Gray-Weale AC, Graham JC, Burnett JR, Byrne K, Lusby RJ. Carotid artery atheroma: comparison of preoperative B-mode ultrasound appearance with carotid endarterectomy specimen pathology. J Cardiovasc Surg (Torino). 1988;29(6):676-681.
39. Prahl U, Holdfeldt P, Bergstrom G, Fagerberg B, Hulthe J, Gustavsson T. Percentage white: a new feature for ultrasound classification of plaque echogenicity in carotid artery atherosclerosis. Ultrasound Med Biol. 2010;36(2):218-226.
40. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. J Intern Med. 2006;259(5): 493-519.
41. Zarins CK, Giddens DP, Bharadvaj BK, Sottiurai VS, Mabon RF, Glagov S. Carotid bifurcation atherosclerosis. Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress. Circ Res. 1983;53(4):502-514.
42. O'Leary DH, Polak JF, Kronmal RA, et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke. 1992;23(12):1752-1760.
43. Kiechl S, Willeit J. The natural course of atherosclerosis. Part I: incidence and progression. Arterioscler Thromb Vasc Biol. 1999;19(6):1484-1490.
44. Hulthe J, Wikstrand J, Emanuelsson H, Wiklund O, de Feyter PJ, Wendelhag I. Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis. Stroke. 1997;28(6):1189-1194.
45. O'Leary DH, Polak JF, Kronmal RA, et al. Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. Stroke. 1996; 27(2):224-231.
46. Leonsson M, Hulthe J, Oscarsson J, et al. Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors. Clin Endocrinol (Oxf). 2002;57(6):751-759.
47. Wikstrand J, Berglund G, Hedblad B, Hulthe J. Antiatherosclerotic effects of beta-blockers. Am J Cardiol. 2003; 91(12A):25H-29H.
48. Sigurdardottir V, Fagerberg B, Hulthe J. Preclinical atherosclerosis and inflammation in 61-year-old men with newly diagnosed diabetes and established diabetes. Diabetes Care. 2004;27(4): 880-884.
49. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709): 132-140.
50. Hashimoto H, Kitagawa K, Hougaku H, Etani H, Hori M. Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects. Stroke. 2004;35(7): 1625-1630.
51. Schmidt C, Fagerberg B, Wikstrand J, Hulthe J. Multiple risk factor intervention reduces cardiovascular risk in hypertensive patients with echolucent plaques in the carotid artery. J Intern Med. 2003;253(4):430-438.
52. Muscari A, Martignani C, Bastagli L, et al. A comparison of acute phase proteins and traditional risk factors as markers of combined plaque and intima-media thickness and plaque density in carotid and femoral arteries. Eur J Vasc Endovasc Surg. 2003; 26(1):81-87.
53. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):391-397.
54. Cao JJ, Arnold AM, Manolio TA, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation. 2007;116(1):32-38.
55. Cao JJ, Thach C, Manolio TA, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003; 108(2):166-170.
56. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007; 357(22):2248-2261.
57. Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344-1353.
58. Baldassarre D, Porta B, Camera M, et al. Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutr Metab Cardiovasc Dis. 2009;19(7):481-490.
59. Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipidlowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 2001;104(4):387-392.
60. Takayama T, Hiro T, Yamagishi M, et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J. 2009;73(11):2110-2117.
61. Kadoglou NP, Gerasimidis T, Moumtzouoglou A, et al. Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Eur J Vasc Endovasc Surg. 2008;35(6):661-668.
62. Hu G. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia. 2003;46(5):608-617.